Tidepath

More GLP-1 drugs

Liraglutide

Also called Victoza, Saxenda, Xultophy

A once-a-day GLP-1 shot, sold as Victoza for type 2 diabetes and as Saxenda for weight management12.

Status
Approved by the FDA in 2010 for type 2 diabetes, as Victoza, and in 2014 for weight management, as Saxenda; generic versions of both are approved5678.
How it's taken
By injection

What it is

Victoza and Saxenda are both liraglutide, a GLP-1 drug12. GLP-1 is a hormone your gut releases when you eat3. Liraglutide acts on the same receptor: it raises insulin when blood sugar is high, lowers glucagon (a hormone that raises blood sugar), and slows how fast the stomach empties1. The insulin effect depends on blood sugar (it's glucose-dependent), so it fades as blood sugar falls1. GLP-1 also helps control appetite, and its receptor is found in parts of the brain that regulate appetite2. Liraglutide is a lab-made version of GLP-1, nearly identical to the human hormone, with a fatty acid attached1. Your own GLP-1 is broken down by enzymes within minutes1. Liraglutide resists those enzymes and binds to proteins in the blood, and its label gives both as part of why it suits once-a-day use1. Its half-life, the time it takes for half a dose to clear, is about 13 hours; for your own GLP-1 it is 1.5 to 2 minutes1. It also comes mixed with an insulin, insulin degludec, as Xultophy4.

What makes it distinct

The same molecule is approved under two names for two different uses, and both are injected once a day12. Victoza is for blood sugar control, alongside diet and exercise, in adults and children 10 and older with type 2 diabetes, and for lowering the risk of major heart events (a heart attack, a stroke, or death from heart or blood vessel disease) in adults with type 2 diabetes and heart or blood vessel disease1. Saxenda is for losing weight and keeping it off, alongside diet and exercise, in people 12 and older who weigh more than 60 kg and have obesity, and in adults with overweight plus at least one weight-related health condition2.

What the evidence shows

Victoza was studied in adults with type 2 diabetes, on its own and added to other diabetes medicines, including insulin1. In each placebo-controlled trial on its label, HbA1c, a blood test of average blood sugar over the past few months, improved more than on placebo, a dummy treatment1. Its label also includes a trial in children 10 and older with type 2 diabetes1. LEADER, a heart-outcomes trial, enrolled 9,340 adults with type 2 diabetes and high heart risk19. Fewer people had a major heart event on liraglutide than on placebo9. For weight, Saxenda was tested in three 56-week trials in adults and one 56-week trial in adolescents aged 12 to 172. One of the adult trials, SCALE Obesity and Prediabetes, enrolled 3,731 adults without type 2 diabetes210. They took liraglutide or placebo alongside advice on diet and exercise, and people on liraglutide lost more weight than people on placebo210.

Open questions

  • Whether it causes thyroid tumors in people. In animal studies it caused thyroid C-cell tumors (C-cells are a type of cell in the thyroid), and its labels say it isn't known whether that happens in people12.
  • What happens to weight after stopping, which our sources don't cover. The weight results on Saxenda's label were measured while people were taking it, for up to 160 weeks in one group2.
  • Whether Victoza lowers heart risk in people with type 2 diabetes who don't already have heart or blood vessel disease. Its heart trial also enrolled some people who only had risk factors, but its approval for lowering heart risk covers adults who already have the disease1.

Worth knowing

Novo Nordisk says it will stop selling the Saxenda brand in the US, as a business decision, with last shipments to wholesalers in late January 2027, and that the decision isn't about safety or quality11. Generic liraglutide that the FDA rates as equivalent to Saxenda is approved8. Separately, in January 2026 the FDA asked for the warning about suicidal thoughts and behavior to be removed from Saxenda's label, after its review found no increased risk with GLP-1 drugs12. Saxenda's February 2026 label no longer carries that warning2.

Sources

  1. VICTOZA (liraglutide) injection, prescribing information, Novo Nordisk (DailyMed; label effective October 2025)
  2. SAXENDA (liraglutide) injection, prescribing information, Novo Nordisk (DailyMed; label effective February 2026)
  3. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
  4. FDA Purple Book monthly data download, September 2026
  5. Drugs@FDA: NDA 022341, VICTOZA (liraglutide)
  6. Drugs@FDA: NDA 206321, SAXENDA (liraglutide)
  7. FDA press announcement: FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes (December 23, 2024)
  8. Drugs@FDA: ANDA 214568, liraglutide (Teva)
  9. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016 (PubMed 27295427)
  10. Pi-Sunyer X et al. A Randomized, Controlled Trial of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015 (PubMed 26132939)
  11. Novo Nordisk, NovoMedLink: Saxenda product page for US healthcare professionals (discontinuation notice; page footer August 2026)
  12. FDA Drug Safety Communication: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications (January 13, 2026)

More in More GLP-1 drugs